51 results on '"Matthew H. Katz"'
Search Results
2. Data from High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer
- Author
-
Florencia McAllister, Eduardo Vilar, David R. Fogelman, Andrew Futreal, Lei Feng, Matthew H. Katz, Anirban Maitra, Gauri R. Varadhachary, Merve Hasanov, Ester Borras, Maureen E. Mork, Wenli Dong, Jennifer B. Goldstein, Maria F. Montiel, and Sarah A. Bannon
- Abstract
Introduction: We aimed to determine the prevalence and landscape of germline mutations among patients with young-onset pancreatic ductal adenocarcinoma (PDAC) as well as their influence in prognosis.Methods: Patients from two cohorts were studied, the high-risk cohort (HRC), which included 584 PDAC patients who received genetic counseling at The University of Texas MD Anderson Cancer Center, and a general cohort (GC) with 233 metastatic PDAC patients. We defined germline DNA sequencing on 13 known pancreatic cancer susceptibility genes. The prevalence and landscape of mutations were determined, and clinical characteristics including survival were analyzed.Results: A total of 409 patients underwent genetic testing (277 from HRC and 132 from GC). As expected, the HRC had higher prevalence of germline mutations compared with the GC: 17.3% versus 6.81%. The most common mutations in both cohorts were in BRCA1/2 and mismatch-repair (MMR) genes. Patients younger than 60 years old had significantly higher prevalence of germline mutations in both the HRC [odds ratios (OR), 1.93 ± 1.03–3.70, P = 0.039] and GC (4.78 ± 1.10–32.95, P = 0.036). Furthermore, PDAC patients with germline mutations in the GC had better overall survival than patients without mutations (HR, 0.44; 95% CI of HR, 0.25–0.76, P = 0.030).Discussion: Germline mutations are highly prevalent in patients with PDAC of early onset and can be predictive of better outcomes. Considering emerging screening strategies for relatives carrying susceptibility genes as well as impact on therapy choices, genetic counseling and testing should be encouraged in PDAC patients, particularly those of young onset. Cancer Prev Res; 11(11); 679–86. ©2018 AACR.
- Published
- 2023
3. Supplementary Table 3 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
- Author
-
Jason B. Fleming, Matthew H. Katz, Huamin Wang, Ryan M. Thomas, E. Lin, Deyali Chatterjee, David Roife, Ran Zhang, Xavier Chopin-Laly, Ya'an Kang, Mark A. Truty, and Xinqun Li
- Abstract
Multivariate Analysis of Factors Associated with Overall Survival, Recurrence-Free Survival, and Liver-Specific Recurrence-Free Survival.
- Published
- 2023
4. Supplementary Movie (low delta) from A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma
- Author
-
Jason B. Fleming, Eric P. Tamm, Priya Bhosale, Huamin Wang, Matthew H. Katz, Christopher H. Crane, Michael P. Kim, Cullen M. Taniguchi, Anirban Maitra, Mauro Ferrari, Jeffrey E. Lee, Prajnan Das, Rachna T. Shroff, Gauri R. Varadhachary, Milind Javle, Robert A. Wolff, Newsha Nikzad, Mohamed Zaid, Anil Chauhan, Shun Yu, Kim A. Reiss, Naveen Garg, Dali Li, Mayrim V. Rios Perez, Peter C. Park, Huaming Yan, Deyali Chatterjee, Ahmed M. Amer, Muayad Almahariq, Dalia Elganainy, Rong Ye, Brian P. Hobbs, F. Anthony San Lucas, Ya'an Kang, John S. Lowengrub, Vittorio Cristini, Yeonju Lee, and Eugene J. Koay
- Abstract
Mathematical model simulation of low delta tumor growth (lambda = 0.2)
- Published
- 2023
5. Figure S1 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- Author
-
Hector A. Alvarez, Anirban Maitra, Aatur D. Singhi, Matthew H. Katz, Ching-Wei Tzeng, Michael P. Kim, Cullen M. Taniguchi, Paul A. Scheet, Subrata Sen, Nabiollah Kamyabi, Jun Zhao, Yanqing Huang, Paola A. Guerrero, Bret M. Stephens, Feven C. Mulu, F. Anthony San Lucas, Jonathan Huang, Alexander Semaan, and Vincent Bernard
- Abstract
(A) Correlation of gene expression levels in a pancreatic cancer cell line between single cells, bulk cells, and across independent replicates. (Single cell vs Bulk, R2: 0.915 and R2:0.9 for genesBoth {greater than or equal to}1 (N=14,922) and {greater than or equal to}10 (N=11,574) respectively. Independent Cell Replicates, R2: 0.937 and R2: 0.955 for genesBoth {greater than or equal to}1 (N=13,791) and {greater than or equal to}10 (N=10,609) respectively). (B) Scatter plots of number of UMIs against number of genes expressed and percentage of mitochondrial genes expressed per single cell across independent tissue samples from pancreatic lesions (different colors). (C) Violin plots of number of genes, UMIs, and percentage of mitochondrial genes expressed per single cell from tissue samples profiled in this study. (D) Principal components (PC) elbow plot to determine the elbow between the standard deviation of the PC and the number of PCs (11).
- Published
- 2023
6. Table S5 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- Author
-
Hector A. Alvarez, Anirban Maitra, Aatur D. Singhi, Matthew H. Katz, Ching-Wei Tzeng, Michael P. Kim, Cullen M. Taniguchi, Paul A. Scheet, Subrata Sen, Nabiollah Kamyabi, Jun Zhao, Yanqing Huang, Paola A. Guerrero, Bret M. Stephens, Feven C. Mulu, F. Anthony San Lucas, Jonathan Huang, Alexander Semaan, and Vincent Bernard
- Abstract
Pathway analysis among lesions
- Published
- 2023
7. Data from A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma
- Author
-
Jason B. Fleming, Eric P. Tamm, Priya Bhosale, Huamin Wang, Matthew H. Katz, Christopher H. Crane, Michael P. Kim, Cullen M. Taniguchi, Anirban Maitra, Mauro Ferrari, Jeffrey E. Lee, Prajnan Das, Rachna T. Shroff, Gauri R. Varadhachary, Milind Javle, Robert A. Wolff, Newsha Nikzad, Mohamed Zaid, Anil Chauhan, Shun Yu, Kim A. Reiss, Naveen Garg, Dali Li, Mayrim V. Rios Perez, Peter C. Park, Huaming Yan, Deyali Chatterjee, Ahmed M. Amer, Muayad Almahariq, Dalia Elganainy, Rong Ye, Brian P. Hobbs, F. Anthony San Lucas, Ya'an Kang, John S. Lowengrub, Vittorio Cristini, Yeonju Lee, and Eugene J. Koay
- Abstract
Purpose:Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with variable presentations and natural histories of disease. We hypothesized that different morphologic characteristics of PDAC tumors on diagnostic computed tomography (CT) scans would reflect their underlying biology.Experimental Design:We developed a quantitative method to categorize the PDAC morphology on pretherapy CT scans from multiple datasets of patients with resectable and metastatic disease and correlated these patterns with clinical/pathologic measurements. We modeled macroscopic lesion growth computationally to test the effects of stroma on morphologic patterns, hypothesizing that the balance of proliferation and local migration rates of the cancer cells would determine tumor morphology.Results:In localized and metastatic PDAC, quantifying the change in enhancement on CT scans at the interface between tumor and parenchyma (delta) demonstrated that patients with conspicuous (high-delta) tumors had significantly less stroma, higher likelihood of multiple common pathway mutations, more mesenchymal features, higher likelihood of early distant metastasis, and shorter survival times compared with those with inconspicuous (low-delta) tumors. Pathologic measurements of stromal and mesenchymal features of the tumors supported the mathematical model's underlying theory for PDAC growth.Conclusions:At baseline diagnosis, a visually striking and quantifiable CT imaging feature reflects the molecular and pathological heterogeneity of PDAC, and may be used to stratify patients into distinct subtypes. Moreover, growth patterns of PDAC may be described using physical principles, enabling new insights into diagnosis and treatment of this deadly disease.
- Published
- 2023
8. Supplementary figure 1 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
- Author
-
Jason B. Fleming, Matthew H. Katz, Paul J. Chiao, Eugene J. Koay, Yu Wang, Ryan M. Thomas, Huamin Wang, Deyali Chatterjee, Mark J. Truty, Michael Pratt, BingBing Dai, Xinqun Li, Mayrim V. Rios Perez, Jianhua Ling, Rei Suzuki, Hailong Lv, Yeonju Lee, David Roife, and Ya'an Kang
- Abstract
Vectra Image analysis workflow, Double IF staining of lumican and collagen I, and TGF-β secretion in HPSC.
- Published
- 2023
9. Data from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- Author
-
Hector A. Alvarez, Anirban Maitra, Aatur D. Singhi, Matthew H. Katz, Ching-Wei Tzeng, Michael P. Kim, Cullen M. Taniguchi, Paul A. Scheet, Subrata Sen, Nabiollah Kamyabi, Jun Zhao, Yanqing Huang, Paola A. Guerrero, Bret M. Stephens, Feven C. Mulu, F. Anthony San Lucas, Jonathan Huang, Alexander Semaan, and Vincent Bernard
- Abstract
Purpose:Early detection of pancreatic ductal adenocarcinoma (PDAC) remains elusive. Precursor lesions of PDAC, specifically intraductal papillary mucinous neoplasms (IPMNs), represent a bona fide pathway to invasive neoplasia, although the molecular correlates of progression remain to be fully elucidated. Single-cell transcriptomics provides a unique avenue for dissecting both the epithelial and microenvironmental heterogeneities that accompany multistep progression from noninvasive IPMNs to PDAC.Experimental Design:Single-cell RNA sequencing was performed through droplet-based sequencing on 5,403 cells from 2 low-grade IPMNs (LGD-IPMNs), 2 high-grade IPMNs (HGD-IPMN), and 2 PDACs (all surgically resected).Results:Analysis of single-cell transcriptomes revealed heterogeneous alterations within the epithelium and the tumor microenvironment during the progression of noninvasive dysplasia to invasive cancer. Although HGD-IPMNs expressed many core signaling pathways described in PDAC, LGD-IPMNs harbored subsets of single cells with a transcriptomic profile that overlapped with invasive cancer. Notably, a proinflammatory immune component was readily seen in low-grade IPMNs, composed of cytotoxic T cells, activated T-helper cells, and dendritic cells, which was progressively depleted during neoplastic progression, accompanied by infiltration of myeloid-derived suppressor cells. Finally, stromal myofibroblast populations were heterogeneous and acquired a previously described tumor-promoting and immune-evading phenotype during invasive carcinogenesis.Conclusions:This study demonstrates the ability to perform high-resolution profiling of the transcriptomic changes that occur during multistep progression of cystic PDAC precursors to cancer. Notably, single-cell analysis provides an unparalleled insight into both the epithelial and microenvironmental heterogeneities that accompany early cancer pathogenesis and might be a useful substrate to identify targets for cancer interception.See related commentary by Hernandez-Barco et al., p. 2027
- Published
- 2023
10. Table S2 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- Author
-
Hector A. Alvarez, Anirban Maitra, Aatur D. Singhi, Matthew H. Katz, Ching-Wei Tzeng, Michael P. Kim, Cullen M. Taniguchi, Paul A. Scheet, Subrata Sen, Nabiollah Kamyabi, Jun Zhao, Yanqing Huang, Paola A. Guerrero, Bret M. Stephens, Feven C. Mulu, F. Anthony San Lucas, Jonathan Huang, Alexander Semaan, and Vincent Bernard
- Abstract
Cell phenotype gene list
- Published
- 2023
11. Supplementary figure 2 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
- Author
-
Jason B. Fleming, Matthew H. Katz, Paul J. Chiao, Eugene J. Koay, Yu Wang, Ryan M. Thomas, Huamin Wang, Deyali Chatterjee, Mark J. Truty, Michael Pratt, BingBing Dai, Xinqun Li, Mayrim V. Rios Perez, Jianhua Ling, Rei Suzuki, Hailong Lv, Yeonju Lee, David Roife, and Ya'an Kang
- Abstract
Lumican expression and secretion in HPaSteC with or without TGF-β exposure at 8 and 24 hours.
- Published
- 2023
12. Table S3 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- Author
-
Hector A. Alvarez, Anirban Maitra, Aatur D. Singhi, Matthew H. Katz, Ching-Wei Tzeng, Michael P. Kim, Cullen M. Taniguchi, Paul A. Scheet, Subrata Sen, Nabiollah Kamyabi, Jun Zhao, Yanqing Huang, Paola A. Guerrero, Bret M. Stephens, Feven C. Mulu, F. Anthony San Lucas, Jonathan Huang, Alexander Semaan, and Vincent Bernard
- Abstract
Differentially expressed genes across all clusters
- Published
- 2023
13. Supplementary figure 3 from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
- Author
-
Jason B. Fleming, Matthew H. Katz, Paul J. Chiao, Eugene J. Koay, Yu Wang, Ryan M. Thomas, Huamin Wang, Deyali Chatterjee, Mark J. Truty, Michael Pratt, BingBing Dai, Xinqun Li, Mayrim V. Rios Perez, Jianhua Ling, Rei Suzuki, Hailong Lv, Yeonju Lee, David Roife, and Ya'an Kang
- Abstract
Lumican secretion associated with cell matrix migration.
- Published
- 2023
14. Figure S5 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- Author
-
Hector A. Alvarez, Anirban Maitra, Aatur D. Singhi, Matthew H. Katz, Ching-Wei Tzeng, Michael P. Kim, Cullen M. Taniguchi, Paul A. Scheet, Subrata Sen, Nabiollah Kamyabi, Jun Zhao, Yanqing Huang, Paola A. Guerrero, Bret M. Stephens, Feven C. Mulu, F. Anthony San Lucas, Jonathan Huang, Alexander Semaan, and Vincent Bernard
- Abstract
Tapestation traces following (A) cDNA amplification of single cell and (B) library construction demonstrating sufficient quality and yield of material. Vertical lines demonstrate regions utilized to calculate cDNA and library yield through area under the curve.
- Published
- 2023
15. Table S4 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- Author
-
Hector A. Alvarez, Anirban Maitra, Aatur D. Singhi, Matthew H. Katz, Ching-Wei Tzeng, Michael P. Kim, Cullen M. Taniguchi, Paul A. Scheet, Subrata Sen, Nabiollah Kamyabi, Jun Zhao, Yanqing Huang, Paola A. Guerrero, Bret M. Stephens, Feven C. Mulu, F. Anthony San Lucas, Jonathan Huang, Alexander Semaan, and Vincent Bernard
- Abstract
Pancreatic cancer core signaling pathways across lesion types
- Published
- 2023
16. Supplementary Methods from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
- Author
-
Jason B. Fleming, Matthew H. Katz, Huamin Wang, Ryan M. Thomas, E. Lin, Deyali Chatterjee, David Roife, Ran Zhang, Xavier Chopin-Laly, Ya'an Kang, Mark A. Truty, and Xinqun Li
- Abstract
Clinical Correlation Studies, Tissue Microarray and Statistical Analysis.
- Published
- 2023
17. Supplementary Methods from A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma
- Author
-
Jason B. Fleming, Eric P. Tamm, Priya Bhosale, Huamin Wang, Matthew H. Katz, Christopher H. Crane, Michael P. Kim, Cullen M. Taniguchi, Anirban Maitra, Mauro Ferrari, Jeffrey E. Lee, Prajnan Das, Rachna T. Shroff, Gauri R. Varadhachary, Milind Javle, Robert A. Wolff, Newsha Nikzad, Mohamed Zaid, Anil Chauhan, Shun Yu, Kim A. Reiss, Naveen Garg, Dali Li, Mayrim V. Rios Perez, Peter C. Park, Huaming Yan, Deyali Chatterjee, Ahmed M. Amer, Muayad Almahariq, Dalia Elganainy, Rong Ye, Brian P. Hobbs, F. Anthony San Lucas, Ya'an Kang, John S. Lowengrub, Vittorio Cristini, Yeonju Lee, and Eugene J. Koay
- Abstract
Additional methods
- Published
- 2023
18. Data from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
- Author
-
Jason B. Fleming, Matthew H. Katz, Huamin Wang, Ryan M. Thomas, E. Lin, Deyali Chatterjee, David Roife, Ran Zhang, Xavier Chopin-Laly, Ya'an Kang, Mark A. Truty, and Xinqun Li
- Abstract
Purpose: To evaluate the relevance between lumican expression patterns and the clinical course of patients with pancreatic ductal adenocarcinoma (PDAC), and to investigate the role of lumican in PDAC progression.Experimental Design: One hundred thirty-one patient tumors were chosen for tissue microarray staining, and Cox regression analysis was used to test the associations between lumican expression and clinical, pathologic, and oncologic outcomes in all patients. Primary PDAC cells and recombinant human lumican protein were used to establish a working model to mimic the in vivo interactions between stromal lumican and PDAC cells. Using this model, we tested the effects of lumican on EGFR signaling via Akt and hypoxia-inducible factor-1α (HIF1α) and its subsequent influence on glucose consumption, lactate production, intracellular ATP, and apoptotic cell death.Results: Lumican was present in the stroma surrounding PDAC cells in roughly one-half of primary tumors and the direct xenografts. Patients with stromal lumican were associated with a profound reduction in metastatic recurrence after surgery and 3-fold longer survival than patients without stromal lumican. In PDAC cells, extracellular lumican reduced EGFR expression and phosphorylation through enhanced dimerization and internalization of EGFR and the resultant inhibition of Akt kinase activity. Lumican also reduced HIF1α expression and activity via Akt. PDAC cells with enhanced HIF1α activity were resistant to lumican-induced inhibition of glucose consumption, lactate production, intracellular ATP, and apoptosis.Conclusions: There is a positive association between stromal lumican in primary PDAC tumors and prolonged survival after tumor resection. Lumican plays a restrictive role in EGFR-expressing pancreatic cancer progression. Clin Cancer Res; 20(24); 6529–40. ©2014 AACR.
- Published
- 2023
19. Figure S3 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- Author
-
Hector A. Alvarez, Anirban Maitra, Aatur D. Singhi, Matthew H. Katz, Ching-Wei Tzeng, Michael P. Kim, Cullen M. Taniguchi, Paul A. Scheet, Subrata Sen, Nabiollah Kamyabi, Jun Zhao, Yanqing Huang, Paola A. Guerrero, Bret M. Stephens, Feven C. Mulu, F. Anthony San Lucas, Jonathan Huang, Alexander Semaan, and Vincent Bernard
- Abstract
Feature Plot of characteristic genes plotted across tSNE clusters demonstrating stromal phenotypes.
- Published
- 2023
20. Supplementary Table 1 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
- Author
-
Jason B. Fleming, Matthew H. Katz, Huamin Wang, Ryan M. Thomas, E. Lin, Deyali Chatterjee, David Roife, Ran Zhang, Xavier Chopin-Laly, Ya'an Kang, Mark A. Truty, and Xinqun Li
- Abstract
Clinicopathologic and oncologic outcome correlation of lumican expression subgroups.
- Published
- 2023
21. Data from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
- Author
-
Jason B. Fleming, Matthew H. Katz, Paul J. Chiao, Eugene J. Koay, Yu Wang, Ryan M. Thomas, Huamin Wang, Deyali Chatterjee, Mark J. Truty, Michael Pratt, BingBing Dai, Xinqun Li, Mayrim V. Rios Perez, Jianhua Ling, Rei Suzuki, Hailong Lv, Yeonju Lee, David Roife, and Ya'an Kang
- Abstract
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is lethal cancer whose primary tumor is characterized by dense composition of cancer cells, stromal cells, and extracellular matrix (ECM) composed largely of collagen. Within the PDAC tumor microenvironment, activated pancreatic stellate cells (PSC) are the dominant stromal cell type and responsible for collagen deposition. Lumican is a secreted proteoglycan that regulates collagen fibril assembly. We have previously identified that the presence of lumican in the ECM surrounding PDAC cells is associated with improved patient outcome after multimodal therapy and surgical removal of localized PDAC.Experimental Design: Lumican expression in PDAC from 27 patients was determined by IHC and quantitatively analyzed for colocalization with PSCs. In vitro studies examined the molecular mechanisms of lumican transcription and secretion from PSCs (HPSCs and HPaSteC), and cell adhesion and migration assays examined the effect of lumican on PSCs in a collagen-rich environment.Results: Here we identify PSCs as a significant source of extracellular lumican production through quantitative IHC analysis. We demonstrate that the cytokine, TGF-β, negatively regulates lumican gene transcription within HPSCs through its canonical signaling pathway and binding of SMAD4 to novel SBEs identified within the promoter region. In addition, we found that the ability of HPSCs to produce and secrete extracellular lumican significantly enhances HPSCs adhesion and mobility on collagen.Conclusions: Our results demonstrate that activated pancreatic stellate cells within PDAC secrete lumican under the negative control of TGF-β; once secreted, the extracellular lumican enhances stellate cell adhesion and mobility in a collagen-rich environment. Clin Cancer Res; 22(19); 4934–46. ©2016 AACR.
- Published
- 2023
22. Supplementary Table 2 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
- Author
-
Jason B. Fleming, Matthew H. Katz, Huamin Wang, Ryan M. Thomas, E. Lin, Deyali Chatterjee, David Roife, Ran Zhang, Xavier Chopin-Laly, Ya'an Kang, Mark A. Truty, and Xinqun Li
- Abstract
Univariate analysis of factors associated with overall survival, recurrence-free survival, and liver-specific recurrence-free survival.
- Published
- 2023
23. Table S1 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- Author
-
Hector A. Alvarez, Anirban Maitra, Aatur D. Singhi, Matthew H. Katz, Ching-Wei Tzeng, Michael P. Kim, Cullen M. Taniguchi, Paul A. Scheet, Subrata Sen, Nabiollah Kamyabi, Jun Zhao, Yanqing Huang, Paola A. Guerrero, Bret M. Stephens, Feven C. Mulu, F. Anthony San Lucas, Jonathan Huang, Alexander Semaan, and Vincent Bernard
- Abstract
Patient characteristics
- Published
- 2023
24. Figure S4 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- Author
-
Hector A. Alvarez, Anirban Maitra, Aatur D. Singhi, Matthew H. Katz, Ching-Wei Tzeng, Michael P. Kim, Cullen M. Taniguchi, Paul A. Scheet, Subrata Sen, Nabiollah Kamyabi, Jun Zhao, Yanqing Huang, Paola A. Guerrero, Bret M. Stephens, Feven C. Mulu, F. Anthony San Lucas, Jonathan Huang, Alexander Semaan, and Vincent Bernard
- Abstract
Correlation heatmap of Pearson correlation coefficients of hierarchically clustered individual cells across stromal populations identified by originating lesion type and tSNE cluster suggests multiple unique subtypes.
- Published
- 2023
25. Figure S2 from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- Author
-
Hector A. Alvarez, Anirban Maitra, Aatur D. Singhi, Matthew H. Katz, Ching-Wei Tzeng, Michael P. Kim, Cullen M. Taniguchi, Paul A. Scheet, Subrata Sen, Nabiollah Kamyabi, Jun Zhao, Yanqing Huang, Paola A. Guerrero, Bret M. Stephens, Feven C. Mulu, F. Anthony San Lucas, Jonathan Huang, Alexander Semaan, and Vincent Bernard
- Abstract
(A) Gross pathology of a HGD-IPMN lesion with concomitant PDAC included in this study. (B) Paraffin fixed tissue H&E sections of representative LGD-IPMN and HGD-IPMN lesions included in this study (20x magnification).
- Published
- 2023
26. Supplementary Materials and Methods from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
- Author
-
Jason B. Fleming, Matthew H. Katz, Paul J. Chiao, Eugene J. Koay, Yu Wang, Ryan M. Thomas, Huamin Wang, Deyali Chatterjee, Mark J. Truty, Michael Pratt, BingBing Dai, Xinqun Li, Mayrim V. Rios Perez, Jianhua Ling, Rei Suzuki, Hailong Lv, Yeonju Lee, David Roife, and Ya'an Kang
- Abstract
HPaSteC and Media: Western blot and ELISA assay: Vectra Automated Quantitative Pathology Imaging System (VAQPIS, PerkinElmer): Double Immunofluorescence staining (IF), and Vectra multispectral analysis: Supplementary figure legends
- Published
- 2023
27. Supplementary tables from Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors
- Author
-
Jason B. Fleming, Matthew H. Katz, Paul J. Chiao, Eugene J. Koay, Yu Wang, Ryan M. Thomas, Huamin Wang, Deyali Chatterjee, Mark J. Truty, Michael Pratt, BingBing Dai, Xinqun Li, Mayrim V. Rios Perez, Jianhua Ling, Rei Suzuki, Hailong Lv, Yeonju Lee, David Roife, and Ya'an Kang
- Abstract
Supplementary Table 1. Wild type and mutant lumican SBE oligos for EMSA. Supplementary Table 2. Clinicopathologic and oncologic outcome correlation of stromal lumican expression in PDAC. Supplementary Table 3. Amount of Lumican Secretion in HPSC and PDACs Supernatant at 8 and 24 hours.
- Published
- 2023
28. Supplemental legend from Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression
- Author
-
Hector A. Alvarez, Anirban Maitra, Aatur D. Singhi, Matthew H. Katz, Ching-Wei Tzeng, Michael P. Kim, Cullen M. Taniguchi, Paul A. Scheet, Subrata Sen, Nabiollah Kamyabi, Jun Zhao, Yanqing Huang, Paola A. Guerrero, Bret M. Stephens, Feven C. Mulu, F. Anthony San Lucas, Jonathan Huang, Alexander Semaan, and Vincent Bernard
- Abstract
Supplemental legend
- Published
- 2023
29. Supplementary Movie (high delta) from A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma
- Author
-
Jason B. Fleming, Eric P. Tamm, Priya Bhosale, Huamin Wang, Matthew H. Katz, Christopher H. Crane, Michael P. Kim, Cullen M. Taniguchi, Anirban Maitra, Mauro Ferrari, Jeffrey E. Lee, Prajnan Das, Rachna T. Shroff, Gauri R. Varadhachary, Milind Javle, Robert A. Wolff, Newsha Nikzad, Mohamed Zaid, Anil Chauhan, Shun Yu, Kim A. Reiss, Naveen Garg, Dali Li, Mayrim V. Rios Perez, Peter C. Park, Huaming Yan, Deyali Chatterjee, Ahmed M. Amer, Muayad Almahariq, Dalia Elganainy, Rong Ye, Brian P. Hobbs, F. Anthony San Lucas, Ya'an Kang, John S. Lowengrub, Vittorio Cristini, Yeonju Lee, and Eugene J. Koay
- Abstract
Mathematical model simulation of high delta tumor growth (lambda = 1.5)
- Published
- 2023
30. A decade's experience of managing suspected pancreatic adenocarcinoma at a tertiary cancer center
- Author
-
Ikenna K, Emelogu, Donald R, Campbell, Gandhi, Lanke, Abraham C, Yu, Graciela, Nogueras-Gonzalez, Phillip, Lum, Emmanuel, Coronel, Phillip S, Ge, William A, Ross, Brian R, Weston, Matthew H, Katz, and Jeffrey H, Lee
- Abstract
We present our experience and established management strategy for endoscopic ultrasonography-guided fine-needle aspiration (EUS-FNA) in diagnosing suspected pancreatic neoplasms at a tertiary referral cancer hospital.Relevant data were extracted from our database for patients who underwent EUS-FNA for suspected pancreatic neoplasms at our institution between 2007 and 2016.Among the 309 patients, the median age was 67 years and 56% were men. The most common presenting symptoms were abdominal pain (37%) and jaundice (29%). Concordance between radiographic diagnosis and final pathology was 89%. The mean lesion size was 34.9 mm on computed tomography and 31.5 mm on EUS. There were 197 patients (64%) with localized disease, of whom 115 (58%) had resectable lesions, 61 (31%) had borderline resectable, and 21 (11%) had unresectable lesions (mean CA 19-9 levels 1705 U/mL, 2490 U/mL, and 479 U/mL, respectively). A median of 3 FNA passes were performed to establish a pathologic diagnosis. Two patients (1%) had postprocedural adverse events. Median overall survival was 47 months in those who underwent surgery after EUS and 12 months in those who did not (P0.001).A multidisciplinary approach is employed for management of suspected pancreatic neoplasm at our tertiary cancer center. A combination of cross-sectional imaging and EUS-FNA serves as a highly effective duo in establishing a tissue diagnosis and staging with a low adverse event rate. Counterintuitively, CA 19-9 is not necessarily higher with resectable lesions than with unresectable lesions, indicating the limitation of CA 19-9 as a pancreatic tumor marker.
- Published
- 2021
31. CT features predictive of nodal positivity at surgery in pancreatic cancer patients following neoadjuvant therapy in the setting of dual energy CT
- Author
-
Ott, Le, Sanaz, Javadi, Priya R, Bhosale, Eugene J, Koay, Matthew H, Katz, Jia, Sun, Wei, Yang, and Eric P, Tamm
- Subjects
Pancreatic Neoplasms ,Lymphatic Metastasis ,Humans ,Tomography, X-Ray Computed ,Neoadjuvant Therapy ,Neoplasm Staging ,Retrospective Studies - Abstract
Evaluate utility of dual energy CT iodine material density images to identify preoperatively nodal positivity in pancreatic cancer patients who underwent neoadjuvant therapy.This IRB approved retrospective study evaluated 62 patients between 2012 and 2016 with proven pancreatic ductal adenocarcinoma, who underwent neoadjuvant therapy, tumor resection and both baseline and preoperative assessment with pancreatic multiphasic rapid switching dual energy CT. Three radiologists in consensus identified on imaging nodes 0.5 cm in short axis, evaluated nodal morphology, size and on each phase density in HU, and concentrations on iodine material density images normalized to the aorta.Of 62 patients, 33 were N0, 20 N1, and 9 N2. Total of 145 lymph nodes were evaluated, with average number of nodes per anatomic site ranging from 1.3 (body tumors) to 5 (uncinate) versus average of 24 and 30 nodes recovered respectively at surgery. Most (N = 44) were pancreatic head tumors. For all patients, regardless of site of primary tumor, the minimum measured iodine value of all of a patient's measured nodes taken as a group on preoperative studies, as normalized to the aorta, was significant at P = 0.041 value in differentiating N0 from N1/2 and ROC analysis showed an AUC of 0.67. With a cutoff of 0.2857, sensitivity was 0.78 and specificity was 0.58, with values 0.2857 indicative of N1/2. Node morphology and changes in nodal size weren't statistically significant.The dual energy based minimum normalized iodine value of all nodes in the surgical field on preoperative studies has modest utility in differentiating N0 from N1/2, and generally outperformed conventional features for identifying nodal metastases.
- Published
- 2020
32. AJCC 8th edition pathologic nodal staging of resected pancreatic adenocarcinoma predicts survival regardless of treatment sequencing
- Author
-
Federico A. Oppliger, Laura R. Prakash, Timothy E. Newhook, Yi-Ju Chiang, Naruhiko Ikoma, Jessica E. Maxwell, Michael P. Kim, Jean-Nicolas Vauthey, Jeffrey E. Lee, Matthew H. Katz, and Ching-Wei D. Tzeng
- Subjects
Adult ,Aged, 80 and over ,Male ,Adenocarcinoma ,Middle Aged ,Neoadjuvant Therapy ,Pancreatic Neoplasms ,Survival Rate ,Pancreatectomy ,Oncology ,Predictive Value of Tests ,Humans ,Female ,Surgery ,Lymph Nodes ,Aged ,Neoplasm Staging ,Retrospective Studies - Abstract
The primary aim was to compare overall survival (OS) between neoadjuvant therapy (NT) and surgery-first (SF) patients with pancreatic adenocarcinoma (PDAC) by nodal stage using the American Joint Commission on Cancer 8th Edition (AJCC8).Rates of nodal positivity are consistently lower following NT versus SF sequencing. It's unclear whether post-NT nodal stage (ypNx) has similar survival compared to SF (pNx) using AJCC8.This is a single-institution retrospective cohort study with routine consideration of NT. Patients undergoing PDAC resection from 2010 to 2018 were analyzed and OS compared by nodal stage using AJCC8.Of 450 total patients, 24% were treated with SF and 76% NT. SF patients had potentially resectable disease in 97% of the cases, whereas NT patients had more advanced clinical stages at diagnosis: borderline resectable 34%, locally advanced 5%. NT patients had higher rates of node-negativity (52.4% vs 22.7%) and lower rates of pathologic N2 disease (19.1% vs 43.6%) vs. SF (p 0.001). For each pathologic nodal stage, SF and NT groups had similar 5-year OS [pN0/ypN0 52.7% vs. 53.6%, p = 0.723], [pN1/ypN1 37.0% vs. 36.7%, p = 0.872], and [pN2/ypN2 16.6% vs. 21.0%, p = 0.508].AJCC8 stratifies outcomes for each post-NT nodal stage similar to SF counterparts. Despite presenting with more advanced clinical stage, NT patients had lower rates of nodal metastases yet comparable OS when stratified by final nodal status. These data provide both hope for patients with obvious radiographic nodal disease at presentation and further support for considering NT sequencing for most patients diagnosed with localized PDAC.
- Published
- 2022
33. Two studies pave the way for preoperative therapy in pancreatic cancer patients
- Author
-
Matthew H, Katz, Syed A, Ahmad, and Judy C, Boughey
- Subjects
Pancreatic Neoplasms ,Survival Rate ,Clinical Trials as Topic ,Pancreatectomy ,Chemotherapy, Adjuvant ,Preoperative Care ,Humans ,Combined Modality Therapy ,Neoadjuvant Therapy ,United States ,Neoplasm Staging - Abstract
The delivery of chemotherapy and/or radiation in the preoperative setting (before surgical resection, instead of after it) has been hypothesized to improve both rates of margin-negative resection and survival.
- Published
- 2017
34. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy
- Author
-
Ahmed M, Amer, Mohamed, Zaid, Baishali, Chaudhury, Dalia, Elganainy, Yeonju, Lee, Christopher T, Wilke, Jordan, Cloyd, Huamin, Wang, Anirban, Maitra, Robert A, Wolff, Gauri, Varadhachary, Michael J, Overman, Jeffery E, Lee, Jason B, Fleming, Ching Wei, Tzeng, Matthew H, Katz, Emma B, Holliday, Sunil, Krishnan, Bruce D, Minsky, Joseph M, Herman, Cullen M, Taniguchi, Prajnan, Das, Christopher H, Crane, Ott, Le, Priya, Bhosale, Eric P, Tamm, and Eugene J, Koay
- Subjects
Adult ,Aged, 80 and over ,Male ,Pancreatic Ducts ,Chemoradiotherapy ,Middle Aged ,Neoadjuvant Therapy ,Pancreatic Neoplasms ,Pancreatectomy ,Treatment Outcome ,Antineoplastic Combined Chemotherapy Protocols ,Feasibility Studies ,Humans ,Female ,Tomography, X-Ray Computed ,Aged ,Carcinoma, Pancreatic Ductal ,Follow-Up Studies ,Neoplasm Staging - Abstract
The assessment of pancreatic ductal adenocarcinoma (PDAC) response to therapy remains challenging. The objective of this study was to investigate whether changes in the tumor/parenchyma interface are associated with response.Computed tomography (CT) scans before and after therapy were reviewed in 4 cohorts: cohort 1 (99 patients with stage I/II PDAC who received neoadjuvant chemoradiation and surgery); cohort 2 (86 patients with stage IV PDAC who received chemotherapy), cohort 3 (94 patients with stage I/II PDAC who received protocol-based neoadjuvant gemcitabine chemoradiation), and cohort 4 (47 patients with stage I/II PDAC who received neoadjuvant chemoradiation and were prospectively followed in a registry). The tumor/parenchyma interface was visually classified as either a type I response (the interface remained or became well defined) or a type II response (the interface became poorly defined) after therapy. Consensus (cohorts 1-3) and individual (cohort 4) visual scoring was performed. Changes in enhancement at the interface were quantified using a proprietary platform.In cohort 1, type I responders had a greater probability of achieving a complete or near-complete pathologic response (21% vs 0%; P = .01). For cohorts 1, 2, and 3, type I responders had significantly longer disease-free and overall survival, independent of traditional covariates of outcomes and of baseline and normalized cancer antigen 19-9 levels. In cohort 4, 2 senior radiologists achieved a κ value of 0.8, and the interface score was associated with overall survival. The quantitative method revealed high specificity and sensitivity in classifying patients as type I or type II responders (with an area under the receiver operating curve of 0.92 in cohort 1, 0.96 in cohort 2, and 0.89 in cohort 3).Changes at the PDAC/parenchyma interface may serve as an early predictor of response to therapy. Cancer 2018;124:1701-9. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
- Published
- 2017
35. Abstract 1547: Expression of epithelial-to-mesenchymal transition markers (EMT) in treated pancreatic duct adenocarcinoma
- Author
-
Matthew H. Katz, Anirban Maitra, Gauri R. Varadhachary, Jeffrey E. Lee, Minhua Wang, Asif Rashid, Robert A. Wolff, Huamin Wang, and Jeannelyn S. Estrella
- Subjects
Pancreatic duct ,Cancer Research ,medicine.anatomical_structure ,Oncology ,Chemistry ,medicine ,Cancer research ,Adenocarcinoma ,Epithelial–mesenchymal transition ,medicine.disease - Abstract
Background: Pancreatic duct adenocarcinoma (PDAC) is an aggressive cancer with poor prognosis. Epithelial to mesenchymal transition (EMT) plays an important role in the progression, metastasis and chemoresistance of PDAC. However the expression of EMT markers and their clinical significance in PDAC patients who received neoadjuvant therapy are not clear. Methods: One hundred and twenty cases were included in this study. All patients received neoadjuvant chemoradiation therapy and underwent surgical resection at our institution from 1999 to 2007. Expressions of EMT markers, including Zeb-1, E-cadherin, vimentin and N-cadherin, were evaluated by immunohistochemistry using tissue microarrays. The staining for Zeb-1 was categorized as positive (≥10% nuclear staining in tumor cells) and negative ( Results: Among 120 cases, 45 (37.5%) were positive for Zeb-1, 25 (20.8 %) were E-cadherin-low, 14 (11.7%) were positive for vimentin, and 2 (1.7%) were positive for N-cadherin. There was negative correlation between the expression of E-cadherin and vimentin (p=0.03). E-cadherin-low and positive vimentin expression correlated with poor differentiation (p=0.02 and p=0.004, respectively). However, no correlations between the EMT markers with other clinical pathologic parameters were found (p>0.05). The median overall survival (OS) and disease-free survival (DFS) were 35.3 ± 2.8 months and 15.9 ± 3.6 months, respectively, in vimentin-negative group compared to 16.1 ± 1.1 months (p=0.03) and 7.0 ± 1.1 months (p=0.02), respectively, in vimentin-positive group. There were no correlation between the expression of Zeb-1, E-cadherin or N-cadherin and survival (P>0.05). In multivariate analysis, expression of vimentin was an independent predictor of shorter OS [HR (95% CI): 2.57 (1.34-4.93), p=0.004] and DFS [HR (95% CI): 2.80 (1.45-5.43), p=0.002]. Conclusion: Our results show that EMT markers are frequently expressed in treated PDAC. Expression of vimentin is a prognostic biomarker for both OS and DFS in patients with PDAC who received neoadjuvent therapy and surgery. Citation Format: Minhua Wang, Jeannelyn S. Estrella, Matthew H. Katz, Asif Rashid, Jeffrey E. Lee, Anirban Maitra, Robert A. Wolff, Gauri R. Varadhachary, Huamin Wang. Expression of epithelial-to-mesenchymal transition markers (EMT) in treated pancreatic duct adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 1547.
- Published
- 2018
36. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer
- Author
-
Michela Capello, Leonidas E. Bantis, Ghislaine Scelo, Yang Zhao, Peng Li, Dilsher S. Dhillon, Nikul J. Patel, Deepali L. Kundnani, Hong Wang, James L. Abbruzzese, Anirban Maitra, Margaret A. Tempero, Randall Brand, Lenka Brennan, Eleonora Feng, Ivana Taguchi, Vladimir Janout, Matthew A. Firpo, Sean J. Mulvihill, Matthew H. Katz, and Samir M. Hanash
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Pathology ,Pancreatic disease ,CA-19-9 Antigen ,endocrine system diseases ,Pancreatitis-Associated Proteins ,Collagen Type VIII ,03 medical and health sciences ,0302 clinical medicine ,Antigens, Neoplasm ,Pancreatitis, Chronic ,Pancreatic cancer ,Internal medicine ,Biomarkers, Tumor ,Humans ,Medicine ,Lectins, C-Type ,Pancreatitis, chronic ,Stage (cooking) ,Aged ,Glycoproteins ,Neoplasm Staging ,Tissue Inhibitor of Metalloproteinase-1 ,business.industry ,Case-control study ,Articles ,Middle Aged ,medicine.disease ,digestive system diseases ,Confidence interval ,Collagen Type XVIII ,Pancreatic Neoplasms ,Insulin-Like Growth Factor Binding Protein 3 ,030104 developmental biology ,ROC Curve ,Receptors, Tumor Necrosis Factor, Type I ,LRG1 ,Area Under Curve ,Case-Control Studies ,030220 oncology & carcinogenesis ,Biomarker (medicine) ,business ,Carcinoma, Pancreatic Ductal - Abstract
Background: CA19-9, which is currently in clinical use as a pancreatic ductal adenocarcinoma (PDAC) biomarker, has limited performance in detecting early-stage disease. We and others have identified protein biomarker candidates that have the potential to complement CA19-9. We have carried out sequential validations starting with 17 protein biomarker candidates to determine which markers and marker combination would improve detection of early-stage disease compared with CA19-9 alone. Methods: Candidate biomarkers were subjected to enzyme-linked immunosorbent assay based sequential validation using independent multiple sample cohorts consisting of PDAC cases (n = 187), benign pancreatic disease (n = 93), and healthy controls (n = 169). A biomarker panel for early-stage PDAC was developed based on a logistic regression model. All statistical tests for the results presented below were one-sided. Results: Six out of the 17 biomarker candidates and CA19-9 were validated in a sample set consisting of 75 PDAC patients, 27 healthy subjects, and 19 chronic pancreatitis patients. A second independent set of 73 early-stage PDAC patients, 60 healthy subjects, and 74 benign pancreatic disease patients (combined validation set) yielded a model that consisted of TIMP1, LRG1, and CA19-9. Additional blinded testing of the model was done using an independent set of plasma samples from 39 resectable PDAC patients and 82 matched healthy subjects (test set). The model yielded areas under the curve (AUCs) of 0.949 (95% confidence interval [CI] = 0.917 to 0.981) and 0.887 (95% CI = 0.817 to 0.957) with sensitivities of 0.849 and 0.667 at 95% specificity in discriminating early-stage PDAC vs healthy subjects in the combined validation and test sets, respectively. The performance of the biomarker panel was statistically significantly improved compared with CA19-9 alone (P < .001, combined validation set; P = .008, test set). Conclusion: The addition of TIMP1 and LRG1 immunoassays to CA19-9 statistically significantly improves the detection of early-stage PDAC.
- Published
- 2016
37. Skin grafts as pharmacological agents: pre-wounding of the donor site
- Author
-
Vincent Falanga, Matthew H. Katz, Robert S. Kirsner, Francisco A. Kerdel, and William H. Eaglstein
- Subjects
medicine.medical_specialty ,medicine.anatomical_structure ,integumentary system ,business.industry ,Tissue replacement ,medicine ,Granulation tissue ,In patient ,Dermatology ,business ,Donor skin ,Surgery - Abstract
Initially thought to act as tissue replacement, cultured epithelial allografts are now known to work by providing a potent stimulus for healing. In a similar fashion, we believe that traditional autografts may also provide a stimulus to help heal chronic wounds, thus acting as pharmacological agents for healing. We attempted to assess the possibility of augmenting the stimulatory properties of donor skin by initiating the healing process in the donor region prior to grafting. This was accomplished by pre-wounding the donor area 3 days prior to harvesting the donor skin. We compared these 'pre-wounded' grafts to those harvested immediately. Two patients underwent punch grafting for chronic leg ulceration. Half of the ulcer was grafted with donor skin harvested from an area that was pre-wounded and the other half from freshly harvested skin. We evaluated each for improvement of granulation tissue and degree of edge effect (migration of the previously dormant wound edges). All the grafts did well. There was marked improvement in granulation tissue in the ulcer bed after grafting, and the obvious presence of an edge effect. The edge effect was increased on the site where the pre-wounded grafts were placed. It may be possible to augment the growth stimulatory properties of donor skin. This may offer therapeutic options in patients with chronic wounds.
- Published
- 1996
38. Feasibility Study of EUS-NOTES as a Novel Approach for Pancreatic Cancer Staging and Therapy: An International Collaborative Study
- Author
-
Adrian Săftoiu, Manoop S. Bhutani, Peter Vilmann, Valeriu Şurlin, Rajesh K Uthamanthil, Jeffrey H Lee, Mehmet Bektas, Harvinder Singh, Dan Ionuţ Gheonea, Ştefan Pătraşcu, Vikas Gupta, Matthew H Katz, and Jason B Fleming
- Subjects
Oncology ,medicine.medical_specialty ,C-Met ,Hepatology ,business.industry ,Gallbladder ,Gallbladder disease ,Gastroenterology ,macromolecular substances ,General Medicine ,Hyperplasia ,medicine.disease ,environment and public health ,chemistry.chemical_compound ,Ezrin ,medicine.anatomical_structure ,chemistry ,Internal medicine ,Cancer research ,Medicine ,Immunohistochemistry ,Adenocarcinoma ,Gallbladder Neoplasm ,business - Abstract
BACKGROUND/AIMS: To investigate the expression of ezrin, HGF and c-met in the benign and malignant lesions of the gallbladder. METHODOLOGY: Ezrin, HGF and c-met expression was detected by immunohistochemistry. RESULTS: The positive ezrin, HGF and c-met expression was significantly higher in gallbladder adenocarcinoma than in benign lesions. The benign lesions with positive ezrin, HGF and/or c-met expression showed moderately- or severely-atypical hyperplastic epithelium. The positive expression of ezrin, HGF and c-met was significantly associated with differentiation, tumor mass, lymph node metastasis and invasion of adenocarcinoma. Univariate Kaplan-Meier analysis showed that increased expression of ezrin, HGF and c-met was associated with decreased overall survival. Multivariate Cox regression analysis showed that increased expression of ezrin, HGF or c-met was an independent bad-prognostic predictor in gallbladder adenocarcinoma. CONCLUSIONS: The expression of ezrin, HGF and/or c-met might be closely related to the carcinogenesis, progression, clinical biological behaviors and prognosis of gallbladder adenocarcinoma.
- Published
- 2012
39. Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis
- Author
-
Qing Zhao, Asif Rashid, Yun Gong, Matthew H. Katz, Jeffrey E. Lee, Robert Wolf, Aparna Balachandran, Gauri R. Varadhachary, Peter W. Pisters, Hua Wang, Henry F. Gomez, James L. Abbruzzese, Jason B. Fleming, and Huamin Wang
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,medicine.medical_treatment ,Adenocarcinoma ,Gastroenterology ,Article ,Disease-Free Survival ,Pathology and Forensic Medicine ,Pancreaticoduodenectomy ,Pancreatectomy ,Pancreatic cancer ,Internal medicine ,medicine ,Carcinoma ,Humans ,Neoadjuvant therapy ,Aged ,business.industry ,Carcinoma in situ ,General Medicine ,Middle Aged ,medicine.disease ,Prognosis ,Neoadjuvant Therapy ,Surgery ,Radiation therapy ,Pancreatic Neoplasms ,Treatment Outcome ,Chemotherapy, Adjuvant ,Female ,Radiotherapy, Adjuvant ,business ,Carcinoma, Pancreatic Ductal ,Follow-Up Studies - Abstract
In patients with pancreatic ductal adenocarcinoma (PDA) who received neoadjuvant therapy and pancreatectomy, pathologic complete response (pCR) is rarely observed and the prognostic significance of pCR is not clear. In this study, we identified 11 patients with pCR (2.5%) from 442 patients with PDA who received neoadjuvant treatment and pancreatectomy from 1995 to 2010. There were 6 men and 5 women, with a median age of 61 years. Four patients had either synchronous or history of extrapancreatic cancer. Five patients received neoadjuvant chemotherapy followed by chemoradiation, and 6 received chemoradiation alone. Ten patients had pancreaticoduodenectomy, and 1 had distal pancreatectomy. Scar and chronic pancreatitis consistent with therapy effect were present in all cases (100%). Pancreatic intraepithelial neoplasia (PanIN) 3/carcinoma in situ was present in 5 cases, and PanIN1 and PanIN2 in 5 cases. However, no residual invasive carcinoma or lymph node metastasis was identified in all cases. Follow-up information was available in 10 patients. Follow-up time ranges from 6 to 194 months (median, 63 months). During the follow-up, 3 patients died of other causes, and 1 developed a second primary PDA in the tail of the pancreas at 84 months after the initial pancreaticoduodenectomy and died at 105 months after the initial diagnosis of PDA. The other 6 patients were alive with no evidence of disease. Patients with pCR had a better survival than did those who had posttherapy stage I or IIA disease (P < .001). Patients with PDA who received neoadjuvant therapy and had pCR in pancreatectomy are rare but have a better prognosis.
- Published
- 2011
40. Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation
- Author
-
Jeannelyn S, Estrella, Asif, Rashid, Jason B, Fleming, Matthew H, Katz, Jeffrey E, Lee, Robert A, Wolf, Gauri R, Varadhachary, Peter W T, Pisters, Eddie K, Abdalla, Jean-Nicolas, Vauthey, Hua, Wang, Henry F, Gomez, Douglas B, Evans, James L, Abbruzzese, and Huamin, Wang
- Subjects
Adult ,Aged, 80 and over ,Male ,Adenocarcinoma ,Middle Aged ,Prognosis ,Combined Modality Therapy ,Disease-Free Survival ,Neoadjuvant Therapy ,Pancreatic Neoplasms ,Chemotherapy, Adjuvant ,Lymphatic Metastasis ,Humans ,Female ,Radiotherapy, Adjuvant ,Aged ,Carcinoma, Pancreatic Ductal ,Neoplasm Staging - Abstract
Neoadjuvant chemoradiation before surgery is an emerging treatment modality for pancreatic ductal adenocarcinoma (PDAC). However, analysis of prognostic factors is limited for patients with PDAC treated with neoadjuvant chemoradiation and pancreaticoduodenectomy (PD).The study population was comprised of 240 consecutive patients with PDAC who received neoadjuvant chemoradiation and PD and was compared with 60 patients who had no neoadjuvant therapy between 1999 and 2007. Clinicopathologic features were correlated with disease-free survival (DFS) and overall survival (OS).Among the 240 treated patients, the 1-year and 3-year DFS rates were 52% and 32%, with a median DFS of 15.1 months. The 1-year and 3-year OS rates were 95% and 47%, with a median OS of 33.5 months. By univariate analysis, DFS was associated with age, post-therapy tumor stage (ypT), lymph node status (ypN), number of positive lymph nodes, and American Joint Committee on Cancer (AJCC) stage, whereas OS was associated with intraoperative blood loss, margin status, ypT, ypN, number of positive lymph nodes, and AJCC stage. By multivariate analysis, DFS was independently associated with age, number of positive lymph nodes, and AJCC stage, and OS was independently associated with differentiation, margin status, number of positive lymph nodes, and AJCC stage. In addition, the treated patients had better OS and lower frequency of lymph node metastasis than those who had no neoadjuvant therapy.In patients with PDAC who received neoadjuvant chemoradiation and subsequent PD, post-therapy pathologic AJCC stage and number of positive lymph nodes are independent prognostic factors.
- Published
- 2011
41. Stanozolol causes rapid pain relief and healing of cutaneous ulcers caused by cryofibrinogenemia
- Author
-
Vincent Falanga, William H. Eaglstein, Francisco A. Kerdel, Matthew H. Katz, and Robert S. Kirsner
- Subjects
Adult ,Male ,medicine.medical_specialty ,Biopsy ,medicine.medical_treatment ,Ecchymosis ,Pain ,Cryofibrinogenemia ,Dermatology ,Skin Ulcer ,Fibrinolysis ,medicine ,Coagulopathy ,Humans ,Cryoglobulins ,Stanozolol ,Aged ,Livedo reticularis ,Chemotherapy ,business.industry ,Fibrinogens, Abnormal ,Fibrinogen ,Thrombosis ,Middle Aged ,medicine.disease ,Surgery ,Purpura ,Cryoglobulinemia ,Female ,medicine.symptom ,business ,Follow-Up Studies ,medicine.drug - Abstract
Background: Cutaneous manifestations of cryofibrinogenemia include purpura, ecchymosis, and ulcerations. The histology of these lesions is characterized by intravascular thrombi. Objective: Our purpose was to test the efficacy of stanozolol, a drug capable of fibrinolytic enhancement, in treating cutaneous ulcers caused by cryofibrinogenemia. Methods: Eight patients with cutaneous ulcerations from cryofibrinogenemia were treated with stanozolol. Plasma cryofibrinogen was measured before and during treatment with stanozolol. Histologic evaluation was also performed before treatment and in selected patients during treatment. Results: After treatment, seven of the eight patients had healing of their ulcers, prompt reduction in their pain, and improvement in livedo reticularis and purpura. Four of the eight patients had no detectable plasma cryofibrinogen after treatment. In addition, dermal intravascular thrombi resolved. Stanozolol was well tolerated and had minimal side effects. Conclusion: We conclude that stanozolol is a safe and effective treatment of the cutaneous manifestations of cryofibrinogenemia.
- Published
- 1993
42. Hypoxia Upregulates the Synthesis of TGF-β1 by Human Dermal Fibroblasts
- Author
-
David Danielpour, Michael B. Sporn, Su Wen Qian, Matthew H. Katz, Vincent Falanga, and Anita B. Roberts
- Subjects
medicine.medical_specialty ,Platelet-derived growth factor ,Transcription, Genetic ,chemistry.chemical_element ,Dermatology ,Biochemistry ,Oxygen ,Dermal fibroblast ,chemistry.chemical_compound ,Transforming Growth Factor beta ,Internal medicine ,medicine ,Humans ,RNA, Messenger ,Fibroblast ,Molecular Biology ,Cells, Cultured ,Skin ,biology ,Cell Biology ,Fibroblasts ,Molecular biology ,Cell Hypoxia ,Up-Regulation ,Oxygen tension ,Endocrinology ,medicine.anatomical_structure ,chemistry ,Cell culture ,biology.protein ,Platelet-derived growth factor receptor ,Transforming growth factor - Abstract
In this report, we have investigated the secretion and synthesis of transforming growth factor-beta 1 (TGF-beta 1) by human dermal fibroblast cultures in response to hypoxia (2% oxygen), and have compared it to standard oxygen culture conditions (15% oxygen at the cell surface). Sandwich enzyme-linked immunosorbent assay (SELISA) showed a selective and progressive increase in secretion of the TGF-beta 1 isoform in response to hypoxia, up to ninefold after cultures were exposed to low oxygen for 72 h; TGF-beta 2 peptide levels were not increased. We then investigated the transcriptional regulation of the TGF-beta 1 gene in response to low and standard oxygen tensions. In the first 24-48 h, TGF-beta 1 mRNA levels decreased steadily in both oxygen environments. This mRNA decline continued for up to 72 h in standard oxygen but not in cultures exposed to low oxygen tension. At 72 h, steady-state TGF-beta 1 mRNA levels were 8 times greater in low compared to standard oxygen, and this increase was reversible upon re-exposure of fibroblast cultures to standard oxygen tension for 24 h. Elevated TGF-beta 1 m-RNA levels in both low and standard oxygen declined steadily and with the same half-life after the addition of actinomycin D, suggesting that hypoxia increased TGF-beta 1 transcription rather than mRNA stability. We conclude that low oxygen tension upregulates the synthesis of TGF-beta 1 by human dermal fibroblasts, and leads to increased secretion of this peptide.
- Published
- 1991
43. Laparoscopic Staging
- Author
-
Matthew H. Katz, Abdool R. Moossa, and Michael Bouvet
- Published
- 2008
44. Common bile duct injection as a novel method for establishing red fluorescent protein (RFP)-expressing human pancreatic cancer in nude mice
- Author
-
Kazuhiko, Tsuji, Meng, Yang, Ping, Jiang, Anirban, Maitra, Sharmeela, Kaushal, Kensuke, Yamauchi, Matthew H, Katz, Abdool R, Moossa, Robert M, Hoffman, and Michael, Bouvet
- Subjects
Pancreatic Neoplasms ,Disease Models, Animal ,Luminescent Proteins ,Mice ,Microscopy, Fluorescence ,Cell Line, Tumor ,Transplantation, Heterologous ,Animals ,Humans ,Mice, Nude ,Cloning, Molecular ,Recombinant Proteins - Abstract
In our previous pancreatic cancer mouse models, we have used surgical orthotopic implantation of human pancreatic tumors to establish clinically relevant fluorescent mouse models of pancreatic cancer.Since exocrine pancreatic cancer is thought to arise from the cells lining the ducts of the pancreas, we hypothesized that direct injection of tumor cells into the common bile duct would also result in pancreatic tumor formation and metastasis.In this study we injected a suspension of the low passage human pancreatic cancer cell line xPA-1 transfected with red fluorescent protein into the common bile duct of nude mice.Pancreatic tumor growth and metastasis formation was monitored by intravital and whole body fluorescent imaging. Single fluorescent pancreatic cancer cells were imaged in the pancreatic duct shortly after injection using the Olympus OV100 Whole Mouse Imaging System.Five days after tumor cell injection in the common bile duct, tumor colonies could be imaged forming within the pancreatic duct. Metastases in the liver were imaged 14 days post common bile duct injection. By day 28, massive tumors were imaged encompassing the entire pancreas. By day 42, RFP-expressing metastases were imaged in the omentum and liver.Common bile duct injection is a novel technique for the development of fluorescent mouse models of metastatic pancreatic cancer.
- Published
- 2006
45. Selective antimetastatic activity of cytosine analog CS-682 in a red fluorescent protein orthotopic model of pancreatic cancer
- Author
-
Matthew H, Katz, Michael, Bouvet, Shinako, Takimoto, Daniel, Spivack, Abdool R, Moossa, and Robert M, Hoffman
- Subjects
Male ,Mice, Nude ,Xenograft Model Antitumor Assays ,Pancreatic Neoplasms ,Cytosine ,Luminescent Proteins ,Mice ,Microscopy, Fluorescence ,Transduction, Genetic ,Weight Loss ,Tumor Cells, Cultured ,Animals ,Humans ,Arabinonucleosides ,Neoplasm Metastasis ,Cell Division - Abstract
In this study we demonstrate the ability of a novel, p.o.-administered cytosine analogue, CS-682, to effectively prolong survival and inhibit metastatic growth in an imageable orthotopic mouse model of pancreatic cancer. MIA-PaCa-2-RFP pancreatic cancer cells were transduced with the Discosoma red fluorescent protein (RFP) and orthotopically implanted onto the pancreas of nude mice. Tumor RFP fluorescence facilitated real-time, sequential imaging, and quantification of primary and metastatic growth and dissemination in vivo. Mice were treated with various p.o. doses of CS-682 on a five times per week schedule until death. At a dose of 40 mg/kg, CS-682 prolonged survival compared with untreated animals (median survival 35 days versus 17 days; P = 0.0008). At nontoxic doses, CS-682 effectively suppressed the rate of primary tumor growth. CS-682 also decreased the development of malignant ascites and the formation of metastases, which were reduced significantly in number in the diaphragm, lymph nodes, liver, and kidney. Selective RFP tumor fluorescence enabled noninvasive real-time comparison between groups during treatment and facilitated identification of micrometastases in solid organs at autopsy. Thus, we have demonstrated that CS-682 is an efficacious antimetastatic agent that significantly prolongs survival in an orthotopic model of pancreatic cancer. The antimetastatic efficacy of CS-682 and its p.o. availability confer significant advantages and clinical potential to this agent for pancreatic cancer.
- Published
- 2003
46. Mo1469 Diagnosis of Pancreatic Adenocarcinoma: a Review of 723 Patients With Solid Pancreatic Neoplasms At a Single Center
- Author
-
Brian R Weston, William A. Ross, Jeffrey H. Lee, Manoop S Bhutani, Somashekar G. Krishna, Abhik Bhattacharya, Kyle Porter, Matthew H. Katz, Jason B. Fleming, and Harshad Ladha
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,Gastroenterology ,medicine ,Adenocarcinoma ,Radiology, Nuclear Medicine and imaging ,CA19-9 ,business ,Single Center ,medicine.disease - Published
- 2014
47. The effects of endothelin-1 on human dermal fibroblast growth and synthetic activity
- Author
-
Matthew H. Katz, Vincent Falanga, Robert S. Kirsner, and Alfred F. Alvarez
- Subjects
medicine.hormone ,Proline ,Biology ,Dermal fibroblast ,Endothelins ,medicine ,Humans ,Fibroblast ,Cells, Cultured ,Skin ,Glucosamine ,Cell growth ,Receptors, Endothelin ,Biological activity ,DNA ,Fibroblasts ,Endothelin 1 ,Molecular biology ,medicine.anatomical_structure ,Biochemistry ,Cell culture ,Surgery ,Collagen ,Fetal bovine serum ,Cell Division - Abstract
Endothelin-1 (ET-1) is the most potent vasoconstricting substance known, and is believed to have a fundamental role in the regulation of blood flow. It is a peptide produced and secreted by endothelial cells in response to hypoxia and injury, as well as by macrophages. These properties suggest that ET-1 may play a role during tissue repair. In this study, we have examined the effects of ET-1 on the growth and synthetic activity of human dermal fibroblasts. ET-1 stimulated DNA synthesis in serum-deprived cultures: this effect reached a mean value of 64% more than control (P < 0.01) at 2.5 ng/ml (10(-9) M) of ET-1. In contrast, the addition of ET-1 to fibroblasts at different densities and in 0, 3, or 10% fetal bovine serum (FBS) failed to increase cell counts. In 1% FBS, a 41% mean increase in cell counts compared to control values was observed in cultures treated with 2.5 ng/ml of ET-1 (P < 0.01). Incubation of dermal fibroblast cultures at 37 degrees C for 1 hr with increasing concentrations of 125I-ET-1 resulted in saturable binding and a half-maximal specific binding of 27.5 pM. Scatchard plot analysis of the binding showed a Kd of 224 pM and 11,400 high-affinity binding sites per cell. ET-1 had no effect on [14C]-glucosamine incorporation by fibroblasts and caused no increase in collagen synthesis, as measured by collagenase-sensitive [3H]proline incorporation and by salt precipitation of 3H-labeled collagen at acid and neutral pH successively.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1992
48. Topical use of human recombinant epidermal growth factor (h-EGF) in venous ulcers
- Author
-
Matthew H. Katz, Vincent Falanga, William H. Eaglstein, Polly Carson, Brian Bucalo, and Brian Harris
- Subjects
Male ,medicine.medical_specialty ,Recombinant Epidermal Growth Factor ,medicine.medical_treatment ,Administration, Topical ,Dermatology ,Single Center ,Placebo ,Gastroenterology ,law.invention ,Varicose Ulcer ,Randomized controlled trial ,Double-Blind Method ,law ,Epidermal growth factor ,Internal medicine ,medicine ,Humans ,Chemotherapy ,Wound Healing ,Epidermal Growth Factor ,business.industry ,Granulation tissue ,Middle Aged ,Bandages ,Recombinant Proteins ,Surgery ,Clinical trial ,medicine.anatomical_structure ,Oncology ,Drug Evaluation ,Female ,business - Abstract
A great deal of interest has been focused recently on the potential use of synthetic polypeptide growth factors to stimulate healing of chronic wounds. In this pilot double-blind randomized study conducted at a single center, we used human recombinant epidermal growth factor (h-EGF) to treat 44 patients with venous ulceration of the lower extremities. An aqueous solution (10 micrograms/mL) of h-EGF was applied topically to the ulcers twice a day until healing occurred or for a maximum of 10 weeks. Patients were evaluated weekly for measurements of ulcer size and for the formation of granulation tissue suitable for grafting. Nine patients were excluded from efficacy evaluation because of protocol violations. Therefore, 35 patients (17 h-EGF, 18 placebo) were evaluable for efficacy, and 44 patients (22 h-EGF, 22 placebo) were available for safety. The median baseline ulcer size for all patients was 18.5 cm2, and was not significantly different between h-EGF and placebo group (12.9 cm2 versus 19.2 cm2, respectively, P = .27). By study end, six (35%) of h-EGF treated patients and two (11%) in the placebo group had healed completely (P = .10). Another 6 patients (2 of 17 h-EGF, 4 of 18 placebo; P = .50) developed healthy granulation tissue that was suitable for grafting. The median ulcer size reduction was 7% for h-EGF versus 3% for placebo per week (P = .29), and 73% versus 33% at study end (P = .32). No untoward side effects were related to the application of h-EGF. We conclude that topical application of h-EGF, in the dose and manner used in this study, was safe but failed to significantly enhance re-epithelialization of venous ulcers. However, a greater reduction in ulcer size and a larger number of healed ulcers with the use of h-EGF are encouraging results.
- Published
- 1992
49. Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth
- Author
-
Matthew H. Katz, Alfred F. Alvarez, Robert S. Kirsner, William H. Eaglstein, and Vincent Falanga
- Subjects
Pathology ,medicine.medical_specialty ,Platelet-derived growth factor ,Time Factors ,Endothelium ,medicine.medical_treatment ,Dermatologic Surgical Procedures ,Cell Count ,Dermatology ,Umbilical vein ,Varicose Ulcer ,Andrology ,chemistry.chemical_compound ,Skin Physiological Phenomena ,medicine ,Humans ,Fibroblast ,Growth Substances ,Cells, Cultured ,Skin ,Platelet-Derived Growth Factor ,Wound Healing ,integumentary system ,business.industry ,Growth factor ,Exudates and Transudates ,Fibroblasts ,Endothelial stem cell ,Molecular Weight ,medicine.anatomical_structure ,chemistry ,Endothelium, Vascular ,Wound healing ,business ,Fetal bovine serum ,Cell Division - Abstract
One proposed mechanism for the beneficial effect of occlusive dressings on healing is the maintenance of contact between the wound bed and accumulated wound fluid, which is thought to contain growth stimulatory substances. We have examined the effect of human wound fluid on the in vitro growth of human dermal fibroblasts and umbilical vein endothelial cells. Acute wound fluid was collected from six patients undergoing split-thickness skin grafting. The acute wound fluid was sterilely collected daily from underneath a vapor-permeable membrane applied to the donor site and changed every 24 hours for 3 days postoperatively. After seeding in optimal growth media (control) on day 0, cultures of human dermal fibroblasts and umbilical vein endothelial cells were supplemented with or without acute wound fluid on the next day (day 1) and on day 3. As determined by cell counts, 2% acute wound fluid stimulated the growth of human dermal fibroblasts (p less than 0.05) and umbilical vein endothelial cells (p less than 0.01) when these cells were cultured in 2% fetal bovine serum and endothelial growth medium, respectively. Wound fluid from postoperative days 1 or 3 caused the same level of stimulation. The addition of an anti-platelet-derived growth factor antibody to wound fluid resulted in a 45% mean reduction in its stimulatory effect on fibroblast growth (p less than 0.02), suggesting that platelet-derived growth factor contributes to the observed effect.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1991
50. Proliferation and collagen synthesis by human dermal fibroblasts cultured from different body sites
- Author
-
Matthew H. Katz, Dean R. Goodless, and Vincent Falanga
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Cell division ,Proline ,Stimulation ,Dermatology ,Biochemistry ,Forearm ,In vivo ,Fibrosis ,medicine ,Humans ,Fibroblast ,Molecular Biology ,Cells, Cultured ,Skin ,integumentary system ,Cell growth ,business.industry ,DNA ,Fibroblasts ,medicine.disease ,Hand ,medicine.anatomical_structure ,Arm ,Collagen ,business ,Fetal bovine serum ,Cell Division ,Thymidine - Abstract
Distal areas in systemic sclerosis (scleroderma), such as the dorsal skin of the hand are more frequently involved and more indurated than proximal areas. On the contrary, the observation often made after surgical excision or trauma is that distal body areas heal more slowly than proximal areas. A possible explanation may be that dermal fibroblasts from distal body parts are more capable, when stimulated, to synthesize greater or lesser amounts of collagen and proliferate at different rates than dermal fibroblasts from more proximal skin. In this study, cultures of dermal fibroblasts from three different body sites (arm, forearm, and hand) of healthy volunteers were investigated for their proliferative activity and collagen synthesis after stimulation in 3% or 10% fetal bovine serum. No significant differences were observed in cell proliferation or in the relative or absolute collagen synthesis by fibroblasts cultured from the hand, forearm or upper arm. We conclude that other in vivo factors are responsible for the observed differences in fibrosis and healing at different body sites. Moreover, if clonal expansion of different fibroblast phenotypes occurs in these physiologic or disease states, it must be of a magnitude that overcomes the fundamental proliferative and biosynthetic baseline.
- Published
- 1991
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.